Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Obstetric Labor Complications, Preeclampsia, Thrombocytopenia
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 445 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Positive affect and self-affect induction; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension, Type 2 Diabetes, Dyslipidemias, Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years and older
Enrollment: 648 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Fort Carson, Colorado • Hinesville, Georgia • Fort Campbell, Kentucky + 3 more

Conditions: Glaucoma
Interventions: Brinzolamide 1% and timolol 0.5% fixed combination eye drops; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 20 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Hypertension
Interventions: valsartan+amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Metabolic Syndrome, Insulin Resistance, Obesity
Interventions: Exercise, Weight Loss; Behavioral
Lead sponsor: Yankton Clinical Research Alliance; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Yankton, South Dakota

Conditions: Pulmonary Arterial Hypertension
Interventions: Placebo, FK506 level < 2 ng/ml, FK506 level 2-3 ng/ml, FK506 level 3-5 ng/ml; Drug
Lead sponsor: Edda Spiekerkoetter; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pulmonary Hypertension Associated With HFpEF
Interventions: TNX-103, Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 45
States / cities: Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle, Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia, Cardiovascular Complication
Interventions: Placebo, Dapagliflozin 10mg Tab; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Motivational interviewing intervention arm; Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 65 Years and older
Enrollment: 727 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Hypertension
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 18
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Potassium estimation algorithm; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Hypertension, Multiple Chronic Conditions
Interventions: Enhanced COACH CDS Tool, Usual Care COACH CDS Tool; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Columbia, Missouri • Portland, Oregon • Nashville, Tennessee

Conditions: Hypertension, Diabetes, Breast Cancer
Interventions: Equity Dashboard, Population Health Coordinator and Community Health Worker Support, Equity Dashboard and Population Health Coordinator Support; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10,766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Esophageal Varices
Interventions: Capsule endoscopy, Esophagogastroduodenoscopy; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 85 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Bipolar Disorder, Non-Adherence, Medication, Hypertension, Major Depressive Disorder
Interventions: iTAB-CV, Self-Monitoring; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pulmonary Arterial Hypertension
Interventions: CT Pulmonary Angiography Scan; Diagnostic Test
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: Not listed
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Glaucoma
Interventions: Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation; Device
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Obesity, Hyperlipidemia, Insulin Resistance, Hypertension
Interventions: Glutathione, N-Acetylcysteine, Placebo; Dietary Supplement · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pulmonary Arterial Hypertension
Interventions: No Intervention; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1,195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2029
U.S. locations: 7
States / cities: Tucson, Arizona • Baltimore, Maryland • Boston, Massachusetts + 4 more

Conditions: Diabetes Mellitus, High Blood Pressure, High Blood Sugar, Hypertension
Interventions: FAM ACT, I-DSMES; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years to 75 Years
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Detroit, Michigan • Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: Nebivolol, Atenolol, Moxifloxacin; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypertension
Interventions: BIO-Z, Finapres Nova; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Platelet Count Trends in Pre-eclamptic Parturients

A Pilot Study of Changing Medication Adherence In Hypertensive African-American Patients

Military Health and Nutrition Examination Study

AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure

One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension

Study of How Exercise or Weight Loss Effects Metabolic Syndrome

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

Motivational Interviewing (MI) Intervention to Improve Adherence

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

Serum Potassium Prediction Using Machine Learning and Single-lead ECG

Collaboration Oriented Approach to Controlling High Blood Pressure

Evaluating the Impact of an Equity Focused Dashboard and Clinical Support

Study of Capsule Endoscopy to Determine the Accuracy for Detection of Esophageal Varices

Using mHealth to Improve Adherence and Reduce Blood Pressure in Individuals With Hypertension and Mood Disorders

The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI

Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

Pulmonary Vascular Disease Phenomics Program PVDOMICS

Comparative Effectiveness of Family vs. Individually Focused Diabetes Education and Support

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

Blood Pressure Monitoring in Hypertensive Populations: Device Testing, Feasibility, Acceptability